Literature DB >> 8413267

Dimerization mediated through a leucine zipper activates the oncogenic potential of the met receptor tyrosine kinase.

G A Rodrigues1, M Park.   

Abstract

Oncogenic activation of the met (hepatocyte growth factor/scatter factor) receptor tyrosine kinase involves a genomic rearrangement that generates a hybrid protein containing tpr-encoded sequences at its amino terminus fused directly to the met-encoded receptor kinase domain. Deletion of Tpr sequences abolishes the transforming ability of this protein, implicating this region in oncogenic activation. We demonstrate, by site-directed mutagenesis and coimmunoprecipitation experiments, that a leucine zipper motif within Tpr mediates dimerization of the tpr-met product and is essential for the transforming activity of the met oncogene. By analogy with ligand-stimulated activation of receptor tyrosine kinases, we propose that constitutive dimerization mediated by a leucine zipper motif within Tpr is responsible for oncogenic activation of the Met kinase. The possibility that this mechanism of activation represents a paradigm for a class of receptor tyrosine kinase oncogenes activated by DNA rearrangement is discussed.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8413267      PMCID: PMC364734          DOI: 10.1128/mcb.13.11.6711-6722.1993

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  64 in total

1.  X-ray structure of the GCN4 leucine zipper, a two-stranded, parallel coiled coil.

Authors:  E K O'Shea; J D Klemm; P S Kim; T Alber
Journal:  Science       Date:  1991-10-25       Impact factor: 47.728

2.  Sequence requirements for coiled-coils: analysis with lambda repressor-GCN4 leucine zipper fusions.

Authors:  J C Hu; E K O'Shea; P S Kim; R T Sauer
Journal:  Science       Date:  1990-12-07       Impact factor: 47.728

3.  ret transforming gene encodes a fusion protein homologous to tyrosine kinases.

Authors:  M Takahashi; G M Cooper
Journal:  Mol Cell Biol       Date:  1987-04       Impact factor: 4.272

4.  Activation of a novel human transforming gene, ret, by DNA rearrangement.

Authors:  M Takahashi; J Ritz; G M Cooper
Journal:  Cell       Date:  1985-09       Impact factor: 41.582

5.  Activation of the trk oncogene by alternatively spliced muscle and non-muscle tropomyosin sequences.

Authors:  D Barnes; L Clayton; G Chumbley; A R MacLeod
Journal:  Oncogene       Date:  1989-02       Impact factor: 9.867

6.  Primary structure of the met protein tyrosine kinase domain.

Authors:  A M Chan; H W King; P R Tempest; E A Deakin; C S Cooper; P Brookes
Journal:  Oncogene       Date:  1987-05       Impact factor: 9.867

7.  Evidence that the leucine zipper is a coiled coil.

Authors:  E K O'Shea; R Rutkowski; P S Kim
Journal:  Science       Date:  1989-01-27       Impact factor: 47.728

8.  BCR first exon sequences specifically activate the BCR/ABL tyrosine kinase oncogene of Philadelphia chromosome-positive human leukemias.

Authors:  A J Muller; J C Young; A M Pendergast; M Pondel; N R Landau; D R Littman; O N Witte
Journal:  Mol Cell Biol       Date:  1991-04       Impact factor: 4.272

9.  Leucine repeats and an adjacent DNA binding domain mediate the formation of functional cFos-cJun heterodimers.

Authors:  R Turner; R Tjian
Journal:  Science       Date:  1989-03-31       Impact factor: 47.728

10.  A point mutation in the extracellular domain of the human CSF-1 receptor (c-fms proto-oncogene product) activates its transforming potential.

Authors:  M F Roussel; J R Downing; C W Rettenmier; C J Sherr
Journal:  Cell       Date:  1988-12-23       Impact factor: 41.582

View more
  52 in total

Review 1.  Dysregulation of Met receptor tyrosine kinase activity in invasive tumors.

Authors:  Alla Danilkovitch-Miagkova; Berton Zbar
Journal:  J Clin Invest       Date:  2002-04       Impact factor: 14.808

2.  Amino acid substitutions of coiled-coil protein Tpr abrogate anchorage to the nuclear pore complex but not parallel, in-register homodimerization.

Authors:  M E Hase; N V Kuznetsov; V C Cordes
Journal:  Mol Biol Cell       Date:  2001-08       Impact factor: 4.138

3.  CD44 is required for two consecutive steps in HGF/c-Met signaling.

Authors:  Véronique Orian-Rousseau; Linfeng Chen; Jonathan P Sleeman; Peter Herrlich; Helmut Ponta
Journal:  Genes Dev       Date:  2002-12-01       Impact factor: 11.361

4.  Oncogenic targeting of an activated tyrosine kinase to the Golgi apparatus in a glioblastoma.

Authors:  Alan Charest; Vicky Kheifets; Julie Park; Keara Lane; Kevin McMahon; Cathy L Nutt; David Housman
Journal:  Proc Natl Acad Sci U S A       Date:  2003-01-21       Impact factor: 11.205

5.  Enhanced signaling and morphological transformation by a membrane-localized derivative of the fibroblast growth factor receptor 3 kinase domain.

Authors:  M K Webster; D J Donoghue
Journal:  Mol Cell Biol       Date:  1997-10       Impact factor: 4.272

6.  Sequential activation of phoshatidylinositol 3-kinase and phospholipase C-gamma2 by the M-CSF receptor is necessary for differentiation signaling.

Authors:  R P Bourette; G M Myles; J L Choi; L R Rohrschneider
Journal:  EMBO J       Date:  1997-10-01       Impact factor: 11.598

7.  The mutationally activated Met receptor mediates motility and metastasis.

Authors:  M Jeffers; M Fiscella; C P Webb; M Anver; S Koochekpour; G F Vande Woude
Journal:  Proc Natl Acad Sci U S A       Date:  1998-11-24       Impact factor: 11.205

8.  A transforming mutation enhances the activity of the c-Kit soluble tyrosine kinase domain.

Authors:  L P Lam; R Y Chow; S A Berger
Journal:  Biochem J       Date:  1999-02-15       Impact factor: 3.857

9.  Association of inhibitory tyrosine protein kinase p50csk with protein tyrosine phosphatase PEP in T cells and other hemopoietic cells.

Authors:  J F Cloutier; A Veillette
Journal:  EMBO J       Date:  1996-09-16       Impact factor: 11.598

Review 10.  Targeting the HGF/c-MET pathway in hepatocellular carcinoma.

Authors:  Lipika Goyal; Mandar D Muzumdar; Andrew X Zhu
Journal:  Clin Cancer Res       Date:  2013-02-06       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.